Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03936153 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03936153 · ClinicalTrials.gov record · last posted 2025-04-10

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

StatusRecruiting
PhasePhase 2
Started2020-01-20
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 10, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Amendment record 11 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 11 times since 2019-05-01; most recent amendment 2025-04-09. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2020-04-29
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT03936153
Lead Sponsor Xynomic Pharmaceuticals, Inc.
Conditions Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment 170 participants
Start Date 2020-01-20
Primary Completion 2026-07-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-10